Stock listing
Lang & Schwarz:853260 Johnson & Johnson Aktie
German listing (Lang & Schwarz) of Johnson & Johnson · home listing NYSE:JNJ
Follow Johnson & Johnson into a list and get an email when it puts out news.
Home listing price · NYSE:JNJ
$270.47 USD -2.23 (-0.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NYSE:JNJ
- Day range
- $269.47 – $272.50 USDNov 20, 2026
- Volume
- 11.92M sharesNov 20, 2026
- Market cap
- $651.1B USDAt the close on Nov 20, 2026 · price × 2.41B shares outstanding
- 52-week range
- $199.91 – $290.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.92B USDMedian day 6.45M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:JNJ · Home | $270.47 USD | -2.23 (-0.8%) | 11,921,706 | $270.36 | $272.50 | $269.47 | $272.70 | Close on Nov 20, 2026 |
| BCBA:JNJ | $32,380 ARS | +1,500 (+4.9%) | 15,029 | $31,080 | $32,820 | $31,080 | $30,880 | Close on Nov 20, 2026 |
| Xetra:JNJ | €247.00 EUR | +5.00 (+2.1%) | 2,427 | €245.10 | €248.25 | €244.45 | €242.00 | Close on Nov 20, 2026 |
| B3:JNJB34 | 105.28 BRL | -3.45 (-3.2%) | 4,831 | 109.82 | 110.00 | 104.00 | 108.73 | Close on Nov 19, 2026 |
| BMV:JNJ | $5,140.01 MXN | +61.01 (+1.2%) | 775 | $5,152.91 | $5,160.00 | $5,130.00 | $5,079.00 | Close on Nov 20, 2026 |
| Cboe Canada:JNJ | $34.49 CAD | +0.66 (+2.0%) | 5,000 | $34.43 | $34.54 | $34.43 | $33.83 | Close on Nov 20, 2026 |
| Frankfurt:JNJ | €246.90 EUR | +4.40 (+1.8%) | — | €245.55 | €248.35 | €243.50 | €242.50 | Close on Nov 20, 2026 |
| Munich:JNJ | €246.40 EUR | +0.25 (+0.1%) | 65 | €245.05 | €246.40 | €245.05 | €246.15 | Close on Nov 20, 2026 |
| Hamburg:JNJ | €246.85 EUR | +5.75 (+2.4%) | — | €244.45 | €246.85 | €244.30 | €241.10 | Close on Nov 20, 2026 |
| Dusseldorf:JNJ | €246.50 EUR | +3.60 (+1.5%) | — | €244.15 | €246.65 | €244.15 | €242.90 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:JNJ · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $270.47 | -2.23 | -0.8% | $270.36 | $272.50 | $269.47 | 11,921,706 | |
| $272.70 | -6.00 | -2.2% | $275.55 | $278.72 | $272.58 | 7,789,258 | |
| $278.70 | -3.85 | -1.4% | $278.99 | $281.72 | $277.56 | 8,051,381 | |
| $282.55 | -3.20 | -1.1% | $288.99 | $290.25 | $282.33 | 7,836,938 | |
| $285.75 | +2.23 | +0.8% | $285.00 | $288.11 | $281.68 | 6,130,885 | |
| $283.52 | +3.11 | +1.1% | $284.38 | $286.08 | $281.00 | 7,677,364 | |
| $280.41 | -0.37 | -0.1% | $277.96 | $281.16 | $276.59 | 5,436,652 | |
| $280.78 | -1.33 | -0.5% | $282.00 | $283.25 | $279.19 | 7,338,513 | |
| $282.11 | +5.89 | +2.1% | $278.00 | $282.73 | $276.20 | 6,894,611 | |
| $276.22 | +3.90 | +1.4% | $267.56 | $276.41 | $265.55 | 8,860,834 | |
| $272.32 | -4.00 | -1.4% | $278.92 | $281.92 | $271.64 | 9,641,967 | |
| $276.32 | +10.15 | +3.8% | $272.41 | $277.35 | $267.67 | 9,540,249 | |
| $266.17 | -4.39 | -1.6% | $268.51 | $271.07 | $265.28 | 6,453,538 | |
| $270.56 | -2.64 | -1.0% | $272.06 | $273.01 | $267.44 | 8,014,235 | |
| $273.20 | -2.00 | -0.7% | $280.00 | $282.02 | $273.13 | 8,948,945 | |
| $275.20 | +4.16 | +1.5% | $275.31 | $278.05 | $273.60 | 5,989,828 | |
| $271.04 | +2.31 | +0.9% | $265.83 | $272.75 | $264.20 | 6,396,275 | |
| $268.73 | +2.43 | +0.9% | $265.25 | $269.09 | $264.83 | 5,774,670 | |
| $266.30 | +2.49 | +0.9% | $266.74 | $272.36 | $264.97 | 5,734,551 | |
| $263.81 | -3.80 | -1.4% | $265.82 | $266.03 | $262.40 | 5,305,727 | |
| $267.61 | +9.83 | +3.8% | $260.54 | $269.67 | $259.04 | 9,711,497 | |
| $257.78 | -1.58 | -0.6% | $257.50 | $257.80 | $254.56 | 6,148,851 | |
| $259.36 | +5.57 | +2.2% | $257.48 | $260.77 | $256.42 | 7,634,901 | |
| $253.79 | -1.77 | -0.7% | $254.43 | $255.56 | $251.52 | 8,678,979 | |
| $255.56 | +2.28 | +0.9% | $255.52 | $257.55 | $254.00 | 6,548,000 | |
| $253.28 | -0.63 | -0.2% | $257.11 | $262.45 | $252.62 | 9,274,700 | |
| $253.91 | +5.30 | +2.1% | $249.10 | $253.94 | $248.50 | 9,662,000 | |
| $248.61 | -15.12 | -5.7% | $254.56 | $256.18 | $245.17 | 16,647,100 | |
| $263.73 | +2.29 | +0.9% | $261.60 | $264.39 | $260.37 | 5,902,500 | |
| $261.44 | +4.96 | +1.9% | $255.09 | $261.61 | $254.99 | 5,726,000 | |
| $256.48 | -1.97 | -0.8% | $256.22 | $257.80 | $251.95 | 6,172,800 | |
| $258.45 | +3.67 | +1.4% | $256.21 | $260.68 | $255.73 | 5,402,200 | |
| $254.78 | +1.85 | +0.7% | $254.15 | $255.48 | $251.17 | 5,661,000 | |
| $252.93 | -3.10 | -1.2% | $256.00 | $256.24 | $252.51 | 10,026,800 | |
| $256.03 | -2.63 | -1.0% | $259.38 | $259.38 | $255.12 | 10,940,400 | |
| $258.66 | -6.08 | -2.3% | $263.68 | $263.98 | $258.33 | 8,289,000 | |
| $264.74 | -2.83 | -1.1% | $267.91 | $268.48 | $264.51 | 6,341,000 | |
| $267.57 | -4.38 | -1.6% | $269.11 | $271.89 | $265.59 | 5,620,500 | |
| $271.95 | +0.73 | +0.3% | $270.17 | $273.78 | $269.27 | 7,185,600 | |
| $271.22 | +0.54 | +0.2% | $271.70 | $272.25 | $269.26 | 4,085,700 | |
| $270.68 | +1.51 | +0.6% | $269.52 | $275.23 | $269.01 | 6,320,600 | |
| $269.17 | -0.02 | 0.0% | $269.47 | $272.14 | $266.50 | 6,632,700 | |
| $269.19 | -0.28 | -0.1% | $267.51 | $270.10 | $265.04 | 5,680,700 | |
| $269.47 | -0.52 | -0.2% | $271.74 | $273.73 | $268.50 | 4,485,300 | |
| $269.99 | -0.23 | -0.1% | $269.45 | $272.11 | $267.20 | 16,428,400 | |
| $270.22 | +2.94 | +1.1% | $268.00 | $270.87 | $267.11 | 6,568,800 | |
| $267.28 | +0.08 | 0.0% | $266.81 | $268.65 | $266.30 | 4,887,300 | |
| $267.20 | +0.88 | +0.3% | $265.81 | $267.20 | $260.68 | 5,283,500 | |
| $266.32 | +0.74 | +0.3% | $271.00 | $271.55 | $266.19 | 4,740,800 | |
| $265.58 | -0.77 | -0.3% | $268.03 | $270.40 | $265.25 | 4,701,200 | |
| $266.35 | -0.73 | -0.3% | $270.21 | $271.27 | $265.72 | 4,929,500 | |
| $267.08 | -2.04 | -0.8% | $268.51 | $270.10 | $266.73 | 6,124,600 | |
| $269.12 | -6.11 | -2.2% | $271.28 | $271.99 | $266.88 | 8,084,700 | |
| $275.23 | -3.20 | -1.1% | $275.13 | $277.80 | $274.75 | 4,320,100 | |
| $278.43 | +3.22 | +1.2% | $277.32 | $278.89 | $273.16 | 5,940,300 | |
| $275.21 | +4.02 | +1.5% | $274.74 | $281.07 | $273.53 | 7,910,600 | |
| $271.19 | +5.34 | +2.0% | $270.83 | $271.91 | $267.02 | 6,033,600 | |
| $265.85 | -2.19 | -0.8% | $267.13 | $267.77 | $265.17 | 7,900,100 | |
| $268.04 | +2.27 | +0.9% | $265.78 | $268.38 | $264.27 | 5,765,600 | |
| $265.77 | -4.23 | -1.6% | $268.45 | $268.45 | $263.83 | 7,306,200 | |
| $270.00 | -3.14 | -1.1% | $271.97 | $272.91 | $269.55 | 7,214,100 | |
| $273.14 | +0.10 | 0.0% | $271.00 | $273.80 | $270.18 | 4,687,000 | |
| $273.04 | +2.80 | +1.0% | $269.74 | $273.98 | $268.57 | 5,436,100 | |
| $270.24 | +2.87 | +1.1% | $267.83 | $272.66 | $267.00 | 6,186,800 | |
| $267.37 | -6.04 | -2.2% | $273.40 | $273.40 | $267.37 | 6,475,900 |
Splits
6 splits since 1970 · NYSE:JNJ · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split | |
| 2-for-1 | Split | |
| 2-for-1 | Split | |
| 2-for-1 | Split | |
| 3-for-1 | Split | |
| 3-for-1 | Split |
- Ticker
- Lang & Schwarz:853260
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 20, 2026
Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness
Latest earnings call · Oct 13, 2026
Johnson & Johnson (NYSE:JNJ) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 13, 2026
Q3 2026 Earnings Presentation
Earnings · 27 slides
Latest news
Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness
Nov 20, 2026
Closed $270.47 (-0.8%) on Nov 20, 2026
Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System
Nov 19, 2026
Closed $270.47 (-0.8%) on Nov 20, 2026
Johnson & Johnson Announces First Commercial Installation of the OTTAVATM Robotic Surgical System at Memorial Hermann Health System
Nov 19, 2026
Closed $270.47 (-0.8%) on Nov 20, 2026
Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication
Nov 19, 2026
Closed $270.47 (-0.8%) on Nov 20, 2026
Johnson & Johnson to Present 13 Abstracts Advancing Neurovascular Science at SVIN 2026
Nov 17, 2026
Closed $278.70 (-1.4%) on Nov 17, 2026
Johnson & Johnson Receives FDA Clearance for Expanded U.S. Ear, Nose and Throat (ENT) Indication for HARMONICTM 1100 Shears
Nov 16, 2026
Closed $282.55 (-1.1%) on Nov 16, 2026
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
Nov 16, 2026
Closed $282.55 (-1.1%) on Nov 16, 2026
California Jury Awards $34.21 Million in Johnson & Johnson Talc-Asbestos Mesothelioma Case
Nov 10, 2026
Closed $280.41 (-0.1%) on Nov 11, 2026
Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
Nov 10, 2026
Closed $280.78 (-0.5%) on Nov 10, 2026
Johnson & Johnson on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 186 in the last 12 months · 208 in all · newest Nov 20, 2026 · oldest 2025
- Calls
- 31 calls with a replay · 31 with a transcript · latest Oct 13, 2026
- Decks
- 69 decks · latest Oct 13, 2026
Where Johnson & Johnson is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:JNJ · Home listing | NYSE | United States | USD |
| gettex:JNJ | gettex | Germany | EUR |
| BCBA:JNJ | BCBA | Argentina | ARS |
| Xetra:JNJ | Xetra | Germany | EUR |
| B3:JNJB34 | B3 | Brazil | BRL |
| Tradegate:JNJ | Tradegate | Germany | EUR |
| SET:JNJ03 | SET | Thailand | THB |
| BCBA:JNJD | BCBA | Argentina | USD |
| TSX:JNJ | TSX | Canada | CAD |
| LS Exchange:853260 | LS Exchange | Germany | EUR |
| BMV:JNJ | BMV | Mexico | MXN |
| Cboe Canada:JNJ | Cboe Canada | Canada | CAD |
| BVC:JNJ | BVC | Colombia | COP |
| Milan:1JNJ | Milan | Italy | EUR |
| Lang & Schwarz:853260 · This page | Lang & Schwarz | Germany | EUR |
| Frankfurt:JNJ | Frankfurt | Germany | EUR |
| Munich:JNJ | Munich | Germany | EUR |
| Turquoise:JNJN | Turquoise | United Kingdom | USD |
| Stuttgart:JNJ | Stuttgart | Germany | EUR |
| LSE:0R34 | LSE | United Kingdom | USD |
| EUROTLX:4JNJ | EUROTLX | Italy | EUR |
| VIE:JNJ | Vienna | Austria | EUR |
| BOATS:JNJ | BOATS | United States | USD |
| BCBA:JNJC | BCBA | Argentina | USD |
| BCS:JNJCL | BCS | Chile | CLP |
| SIX Swiss:JNJ.USD | SIX Swiss | Switzerland | USD |
| Hamburg:JNJ | Hamburg | Germany | EUR |
| Hanover:JNJ | Hanover | Germany | EUR |
| BIVA:JNJ | BIVA | Mexico | MXN |
| BCS:JNJ | BCS | Chile | USD |
| Dusseldorf:JNJ | Dusseldorf | Germany | EUR |
| BX Swiss:JNJ | BX Swiss | Switzerland | CHF |
| BSESOF:JNJ | BSESOF | Bulgaria | EUR |
| SIX Swiss:JNJ | SIX Swiss | Switzerland | CHF |
| BCBA:JNJ.B | BCBA | Argentina | ARS |
| Aquis:JNJD | Aquis | United Kingdom | EUR |
| BVL:JNJUS | BVL | Peru | PEN |
| gettex:JNJ0 | gettex | Germany | EUR |
| BX Swiss:JNJUSD | BX Swiss | Switzerland | USD |
| Aquis:JNJD | Aquis | United Kingdom | EUR |
| Dusseldorf:JNJ0 | Dusseldorf | Germany | EUR |
| Frankfurt:JNJ0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A3ET7S | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3ET7S | LS Exchange | Germany | EUR |
| Munich:JNJ0 | Munich | Germany | EUR |
| BCBA:JNJ.CI | BCBA | Argentina | ARS |
Valuation
P/E 40.5× against a median of 28.8×: 8th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 27, 2026 · price Nov 20, 2026
- Enterprise value
- $678.5B USD
- P/E
- 40.5×
- EV/sales
- 6.8×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 8.0×
- Gross margin
- 67.6%
- Operating margin
- Not reported
- Net margin
- 16.2%
- Debt to equity
- 0.6×
- Beta vs S&P 500
- -0.02
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Johnson & Johnson · NYSE:JNJ | US$651.1B | US$678.5B | 40.5× | 6.8× | n/a | 8.0× | 16.2% | 0.6× | -0.02 |
| Eli Lilly and Company · NYSE:LLY | US$1.27T | US$1.31T | 46.0× | 15.1× | n/a | 31.5× | 31.9% | 1.2× | 0.34 |
| AbbVie Inc. · NYSE:ABBV | US$505.9B | US$503.8B | 48.9× | 7.6× | n/a | n/a | 15.7% | n/a | 0.00 |
| Merck & Company, Inc. · NYSE:MRK | US$329.7B | US$373.8B | 134× | 5.5× | n/a | 7.3× | 3.6% | 1.2× | 0.28 |
| Novartis AG · SIX:NOVN | US$287.4B | US$304.7B | 20.6× | n/a | n/a | 6.2× | n/a | 0.6× | n/a |
| AstraZeneca PLC · LSE:AZN | US$272.1B | US$298.0B | 24.6× | 4.8× | 14.1× | 5.3× | 17.7% | 0.7× | n/a |
| Pfizer, Inc. · NYSE:PFE | US$156.2B | US$207.8B | 38.7× | 3.3× | 9.6× | 1.8× | 6.3% | 0.7× | 0.29 |
| Vertex Pharmaceuticals Incorporated · NASDAQ:VRTX | US$130.6B | US$128.8B | 32.8× | 9.9× | 28.4× | 6.3× | 30.7% | 0.2× | 0.47 |
| Novo Nordisk A/S Class B · OMXCOP:NOVO_B | US$129.4B | US$142.3B | 7.8× | 2.9× | 5.5× | 4.0× | 33.9% | 0.6× | n/a |
| Bristol-Myers Squibb Company · NYSE:BMY | US$120.2B | US$151.3B | 13.0× | 3.0× | n/a | 5.1× | 18.5% | 1.9× | 0.26 |
| Sanofi SA · EURONEXT:SAN | US$111.7B | US$126.9B | 14.6× | 2.3× | 4.7× | 1.4× | 13.9% | 0.3× | n/a |
| Median of the others | US$214.1B | US$252.9B | 28.8× | 4.8× | 9.6× | 5.3× | 17.7% | 0.7× | 0.29 |
Forecasts
11 strong buy · 5 buy · 6 hold · 1 strong sell · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 279.41 USD · Analysts' mean
- EPS, year to Dec 2026
- 11.12 · 21 analysts
- Revenue, year to Dec 2026
- 101.2B · 21 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Joaquin Duato | Chairman and Chief Executive Officer |
| Joseph J. Wolk | Executive Vice President, Chief Financial Officer |
| Paula A. Johnson | President, Wellesley College |
| Elizabeth Forminard | Executive Vice President, Chief Legal Officer |
| Ryan Koors | Vice President, Investor Relations |
| James Swanson | Executive Vice President, Chief Information Officer |
| John C. Reed | Executive Vice President, Innovative Medicine, R&D |
| Kathryn E. Wengel | Executive Vice President, Chief Technical Operations and Risk Officer |
| Kristen Mulholland | Executive Vice President, Chief Human Resources Officer |
| Tim Schmid | Executive Vice President, Worldwide Chairman, MedTech |
| Tom Cavanaugh | Executive Vice President, Worldwide Chairman, Innovative Medicine |
| Vanessa Broadhurst | Executive Vice President, Global Corporate Affairs |
| Mark B. McClellan | Director, Duke-Robert J. Margolis, MD, Center for Health Policy; Margolis Professor of Business, Medicine and Policy, Duke University |
Board
| Director | Role |
|---|---|
| Joaquin Duato | Chairman and Chief Executive Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| Johnson & Johnson (NYSE:JNJ) Q3 2026 Earnings Call | Tue, Oct 13, 2026 · 8:30 AM ET | Replay |
| Johnson & Johnson (NYSE:JNJ) Q2 2026 Earnings Call | Wed, Jul 15, 2026 · 8:30 AM ET | Replay |
| Johnson & Johnson (NYSE:JNJ) Q1 2026 Earnings Call | Tue, Apr 14, 2026 · 8:30 AM ET | Replay |
| Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings Call | Wed, Jan 21, 2026 · 8:30 AM ET | Replay |
| Johnson & Johnson (NYSE:JNJ) Q3 2025 Earnings Call | Tue, Oct 14, 2025 · 8:30 AM ET | Replay |
| Johnson & Johnson (NYSE:JNJ) Q2 2025 Earnings Call | Wed, Jul 16, 2025 · 8:30 AM ET | Replay |
| Johnson & Johnson (NYSE:JNJ) Q1 2025 Earnings Call | Tue, Apr 15, 2025 · 8:30 AM ET | Replay |
| Johnson & Johnson (NYSE:JNJ) Q4 2024 Earnings Call | Wed, Jan 22, 2025 · 8:00 AM ET | Replay |
| Johnson & Johnson (NYSE:JNJ) Q3 2024 Earnings Call | Tue, Oct 15, 2024 · 8:30 AM ET | Replay |
| Johnson & Johnson (NYSE:JNJ) Q2 2024 Earnings Call | Wed, Jul 17, 2024 · 8:30 AM ET | Replay |
All 31 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 13, 2026 · Before open | −5.7% |
| Q2 2026 | Jul 15, 2026 · Before open | −2.7% |
| Q1 2026 | Apr 14, 2026 · Before open | +0.9% |
| Q4 2025 | Jan 21, 2026 · Before open | −0.1% |
| Q3 2025 | Oct 14, 2025 · Before open | −0.0% |
| Q2 2025 | Jul 16, 2025 · Before open | +6.2% |
| Q1 2025 | Apr 15, 2025 · Before open | −0.5% |
| Q4 2024 | Jan 22, 2025 · Before open | −1.9% |
| Q3 2024 | Oct 15, 2024 · Before open | +1.6% |
| Q2 2024 | Jul 17, 2024 · Before open | +3.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 16, 2024 · Before open | −2.1% |
| Q4 2023 | Jan 23, 2024 · Before open | −1.6% |
| Q3 2023 | Oct 17, 2023 · Before open | −0.9% |
| Q2 2023 | Jul 20, 2023 · Before open | +6.1% |
| Q1 2023 | Apr 18, 2023 · Before open | −2.8% |
| Q4 2022 | Jan 24, 2023 · Before open | 0.0% |
| Q3 2022 | Oct 18, 2022 · Before open | −0.3% |
| Q2 2022 | Jul 19, 2022 · Before open | −1.5% |
| Q1 2022 | Apr 19, 2022 · Before open | +3.0% |
| Q4 2021 | Jan 25, 2022 · Before open | +2.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 27 slides | Oct 13, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 24 slides | Jul 15, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 28 slides | Apr 14, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 33 slides | Jan 21, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 26 slides | Oct 14, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 25 slides | Jul 16, 2025 |
| Fact Sheet (July 2025) | Fact sheet | 2 slides | July 2025 |
| Q1 2025 Earnings Presentation | Earnings | 32 slides | Apr 15, 2025 |
| Fact Sheet (April 2025) | Fact sheet | 2 slides | April 2025 |
| Fact Sheet (2025) | Fact sheet | 2 slides | 2025 |
Show 50 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2024 Earnings Presentation | Earnings | 23 slides | Oct 15, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 23 slides | Jul 17, 2024 |
| Fact Sheet (2024) | Fact sheet | 2 slides | Jul 11, 2024 |
| Fact Sheet (July 2024) | Fact sheet | 3 slides | July 2024 |
| Corporate Update (May 2024) | Corporate update | 12 slides | May 1, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 20 slides | Apr 16, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 31 slides | Apr 16, 2024 |
| Shockwave Medical — Merger or Acquisition (April 2024) | Merger or acquisition | 21 slides | Apr 5, 2024 |
| Q4 2023 Earnings Presentation | Earnings | 33 slides | Jan 23, 2024 |
| Investor Day (December 2023) | Investor day | 36 slides | Dec 5, 2023 |
| Investor Day (December 2023) | Investor day | 88 slides | Dec 5, 2023 |
| Investor Day (December 2023) | Investor day | 69 slides | Dec 5, 2023 |
| Investor Day (December 2023) | Investor day | 13 slides | Dec 5, 2023 |
| Investor Day (December 2023) | Investor day | 13 slides | Dec 5, 2023 |
| Q3 2023 Earnings Presentation | Earnings | 21 slides | Oct 17, 2023 |
| Corporate Update (August 2023) | Corporate update | 11 slides | Aug 30, 2023 |
| Merger or Acquisition (July 2023) | Merger or acquisition | 35 slides | Jul 25, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 30 slides | Jul 20, 2023 |
| Fact Sheet (July 2023) | Fact sheet | 2 slides | Jul 5, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 20 slides | Apr 18, 2023 |
| Fact Sheet (March 2023) | Fact sheet | 2 slides | March 2023 |
| Fact Sheet (March 2023) | Fact sheet | 2 slides | March 2023 |
| Fact Sheet (March 2023) | Fact sheet | 2 slides | March 2023 |
| Fact Sheet (March 2023) | Fact sheet | 2 slides | March 2023 |
| Fact Sheet (March 2023) | Fact sheet | 4 slides | March 2023 |
| Fact Sheet (March 2023) | Fact sheet | 2 slides | March 2023 |
| Q4 2022 Earnings Presentation | Earnings | 40 slides | Jan 24, 2023 |
| Technical Presentation (January 2023) | Technical | 34 slides | January 2023 |
| Merger or Acquisition (November 2022) | Merger or acquisition | 22 slides | Nov 1, 2022 |
| Q3 2022 Earnings Presentation | Earnings | 20 slides | Oct 18, 2022 |
| Q2 2022 Earnings Presentation | Earnings | 27 slides | Jul 19, 2022 |
| Fact Sheet (June 2022) | Fact sheet | 2 slides | June 2022 |
| Fact Sheet (May 2022) | Fact sheet | 4 slides | May 27, 2022 |
| Fact Sheet (2022) | Fact sheet | 2 slides | May 12, 2022 |
| Q1 2022 Earnings Presentation | Earnings | 19 slides | Apr 19, 2022 |
| Q4 2021 Earnings Presentation | Earnings | 33 slides | Jan 25, 2022 |
| Fact Sheet (2022) | Fact sheet | 2 slides | 2022 |
| Technical Presentation (December 2021) | Technical | 5 slides | Dec 16, 2021 |
| Q3 2021 Earnings Presentation | Earnings | 19 slides | Oct 19, 2021 |
| nh4h pitch deck slide template | 38 slides | September 2021 |
This page holds 50 of 69 decks. Open Decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.2B | 88.8B | 85.2B | 80.0B | 78.7B | 82.6B | 82.1B | 81.6B | 76.5B | 71.9B |
| Cost of revenue | 30.3B | 27.5B | 26.6B | 24.6B | 23.4B | 28.4B | 27.6B | 27.1B | 25.4B | 21.8B |
| Gross profit | 63.9B | 61.4B | 58.6B | 55.4B | 55.3B | 54.2B | 54.5B | 54.5B | 51.0B | 50.1B |
| Research and development | 109.0M | 1.84B | 483.0M | 0 | 0 | 12.2B | 11.4B | 10.8B | 10.6B | 9.14B |
| Selling, general and administrative | 23.7B | 22.9B | 21.5B | 20.2B | 20.1B | 22.1B | 22.2B | 22.5B | 21.5B | 20.1B |
| Depreciation and amortization | 7.50B | 7.34B | 7.49B | 6.97B | 7.39B | 7.23B | 7.01B | 6.93B | 5.64B | 3.75B |
| Interest expense | 971.0M | 755.0M | 772.0M | 276.0M | 183.0M | 201.0M | 318.0M | 1.00B | 934.0M | 726.0M |
| Income before tax | 32.6B | 16.7B | 15.1B | 19.4B | 19.2B | 16.5B | 17.3B | 18.0B | 17.7B | 19.8B |
| Income tax | 5.78B | 2.62B | 1.74B | 2.99B | 1.38B | 1.78B | 2.21B | 2.70B | 16.4B | 3.26B |
| Net income | 26.8B | 14.1B | 35.2B | 17.9B | 20.9B | 14.7B | 15.1B | 15.3B | 1.30B | 16.5B |
| Earnings per share, basic | 11.13 | 5.84 | 13.88 | 6.83 | 7.93 | 5.59 | 5.72 | 5.70 | 0.48 | 6.04 |
| Earnings per share, diluted | 11.03 | 5.79 | 13.72 | 6.73 | 7.81 | 5.51 | 5.63 | 5.61 | 0.47 | 5.93 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 19.7B | 24.1B | 21.9B | 12.9B | 14.5B | 14.0B | 17.3B | 18.1B | 17.8B | 19.0B |
| Short-term investments | 393.0M | 417.0M | 1.07B | 9.39B | 17.1B | 11.2B | 1.98B | 1.58B | 472.0M | 22.9B |
| Receivables | 17.2B | 14.8B | 14.9B | 14.0B | 15.3B | 13.6B | 14.5B | 14.1B | 13.5B | 11.7B |
| Inventory | 14.2B | 12.4B | 11.2B | 10.3B | 10.4B | 9.34B | 9.02B | 8.60B | 8.77B | 8.14B |
| Current assets | 55.6B | 55.9B | 53.5B | 55.3B | 61.0B | 51.2B | 45.3B | 46.0B | 43.1B | 65.0B |
| Property, plant and equipment | 23.2B | 20.5B | 19.9B | 18.0B | 19.0B | 18.8B | 17.7B | 17.0B | 17.0B | 15.9B |
| Goodwill | 48.8B | 44.2B | 36.6B | 36.0B | 25.4B | 36.4B | 33.6B | 30.5B | 31.9B | 22.8B |
| Total assets | 199.2B | 180.1B | 167.6B | 187.4B | 182.0B | 174.9B | 157.7B | 153.0B | 157.3B | 141.2B |
| Accounts payable | 12.0B | 10.3B | 9.63B | 9.89B | 11.1B | 9.51B | 8.54B | 7.54B | 7.31B | 6.92B |
| Current liabilities | 54.1B | 50.3B | 46.3B | 55.8B | 45.2B | 42.5B | 36.0B | 31.2B | 30.5B | 26.3B |
| Long-term debt | 39.4B | 30.7B | 25.9B | 26.9B | 30.0B | 32.6B | 26.5B | 27.7B | 30.7B | 22.4B |
| Total debt | 49.9B | 38.4B | 30.8B | 41.2B | 35.9B | 37.1B | 27.7B | 33.1B | 36.1B | 28.8B |
| Total liabilities | 117.7B | 108.6B | 98.8B | 110.6B | 108.0B | 111.6B | 98.3B | 93.2B | 97.1B | 70.8B |
| Shareholders' equity | 81.5B | 71.5B | 68.8B | 76.8B | 74.0B | 63.3B | 59.5B | 59.8B | 60.2B | 70.4B |
| Shares outstanding | 2.41B | 2.41B | 2.41B | 2.41B | 2.41B | 2.41B | 2.60B | 2.63B | 2.63B | 2.63B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 24.5B | 24.3B | 22.8B | 21.2B | 23.4B | 23.5B | 23.4B | 22.2B | 21.1B | 18.8B |
| Capital spending | -4.83B | -4.42B | -4.54B | -4.01B | -3.65B | -3.35B | -3.50B | -3.67B | -3.28B | -3.23B |
| Free cash flow | 19.7B | 19.8B | 18.2B | 17.2B | 19.8B | 20.2B | 19.9B | 18.5B | 17.8B | 15.5B |
| Cash from investing | -23.6B | -18.6B | 878.0M | -12.4B | -8.68B | -20.8B | -6.19B | -3.17B | -14.9B | -4.76B |
| Cash from financing | -5.54B | -3.13B | -15.8B | -8.87B | -14.0B | -6.12B | -18.0B | -18.5B | -7.67B | -8.55B |
| Share buybacks | -5.95B | -2.43B | -5.05B | -6.04B | -3.46B | -3.22B | -6.75B | -5.87B | -6.36B | -8.98B |
| Change in cash | -4.40B | 2.25B | 7.73B | -360.0M | 502.0M | -3.32B | -802.0M | 283.0M | -1.15B | 5.24B |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 13F-HR · Fund holdings report | Oct 26, 2026 | Fund holdings report | SEC |
| 10-Q · Quarterly report | Oct 21, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 13, 2026 | Results | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| N-PX | Aug 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 6, 2026 | Other filings | SEC |
| 13F-HR · Fund holdings report | Aug 6, 2026 | Fund holdings report | SEC |
| 144 · Notice of proposed sale | Aug 5, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 4, 2026 | Management or board change | SEC |
| 8-K · Current report | Jul 29, 2026 | Current report | SEC |
| 8-K · Current report | Jul 27, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Jul 23, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 20, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 15, 2026 | Results | SEC |
| 11-K · Annual report of an employee plan | Jun 25, 2026 | Annual report | SEC |
| 11-K · Annual report of an employee plan | Jun 25, 2026 | Annual report | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| SD · Specialized disclosure | May 27, 2026 | ESG report | SEC |
| 13F-HR · Fund holdings report | May 13, 2026 | Fund holdings report | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 1, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 27, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Apr 22, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 14, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 13F-HR/A · Fund holdings report, amended | Mar 18, 2026 | Fund holdings report | SEC |
| 13F-HR/A · Fund holdings report, amended | Mar 18, 2026 | Fund holdings report | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 11, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 11, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 11, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 13F-HR · Fund holdings report | Feb 13, 2026 | Fund holdings report | SEC |
| 144 · Notice of proposed sale | Feb 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| S-3ASR · Registration statement | Feb 11, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 11, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 5, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 5 · Annual statement of ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 26, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 21, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 12, 2026 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 13F-HR · Fund holdings report | Nov 13, 2025 | Fund holdings report | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 22, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 22, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 17, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 14, 2025 | Results | SEC |
| 3 · Initial statement of ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 29, 2025 | Other filings | SEC |
| N-PX | Aug 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 24, 2025 | Quarterly report | SEC |
| 13F-HR · Fund holdings report | Jul 22, 2025 | Fund holdings report | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 17, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 16, 2025 | Results | SEC |
| 3 · Initial statement of ownership | Jul 8, 2025 | Insider trade | SEC |
| 11-K · Annual report of an employee plan | Jun 23, 2025 | Annual report | SEC |
| 11-K · Annual report of an employee plan | Jun 23, 2025 | Annual report | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2025 | Management or board change | SEC |
| SD · Specialized disclosure | May 28, 2025 | ESG report | SEC |
| 13F-HR · Fund holdings report | May 7, 2025 | Fund holdings report | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | May 2, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 30, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Apr 23, 2025 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | Apr 23, 2025 | Other filings | SEC |
| PX14A6G | Apr 23, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 16, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 15, 2025 | Results | SEC |
| 8-K · Current report | Apr 3, 2025 | Current report | SEC |
| PX14A6G | Mar 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Mar 12, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 12, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 12, 2025 | Meeting notice | SEC |
| DFAN14A | Mar 7, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 28, 2025 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Feb 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Feb 26, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 26, 2025 | Current report | SEC |
| DFAN14A | Feb 25, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 25, 2025 | Other filings | SEC |
| 424B2 · Prospectus | Feb 21, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 20, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 424B2 · Prospectus | Feb 19, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Feb 19, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Feb 19, 2025 | Offer document | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Johnson & Johnson’s releases · as of Oct 15, 2026
- Common shares
- 2,407,310,266
- Fully diluted
- 2,407,310,266
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 2,407,310,266 | Oct 15, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 15, 2026 | 2,407,310,266 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bill Weldon Other companies: Heartflow, Inc. (Chairman of the Board of Directors · Since at least Aug 7, 2025); Exxon Mobil Corporation (Director · May 29, 2013 – May 26, 2021 · Past); Chubb Limited (Director · Apr 30, 2013 – Jan 14, 2016 · Past); CVS Health Corporation (Director · Mar 29, 2013 – Nov 17, 2022 · Past); JPMorgan Chase & Co. (Director · Sep 30, 2011 – May 20, 2019 · Past) | Director · Oct 31, 2011 – Dec 13, 2012 · Past |
| John G. Morikis Other companies: United Parcel Service, Inc. (Director · Since at least Jun 2, 2025); Whirlpool Corporation (Director · Since at least Feb 17, 2025); General Mills, Inc. (Director · Since at least Jan 29, 2024); Sherwin-Williams Company (the) (Executive Chairman, Director · Jun 10, 2022 – Feb 18, 2025 · Past); Fortune Brands Innovations, Inc. (Director · May 3, 2022 – May 16, 2023 · Past) | Director · Since at least Sep 8, 2025 |
| Sandra E Peterson Other companies: Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); Microsoft Corp. (Director · Since at least Dec 2, 2015); Zymergen Inc (Director · Apr 21, 2021 – Oct 19, 2022 · Past); Covetrus Inc (Director · Jun 10, 2020 – Oct 13, 2022 · Past); Dun & Bradstreet Holdings Inc. (Director · Mar 29, 2007 – Sep 11, 2015 · Past) | Exec VP, Group WW Chairman · Dec 1, 2012 – Feb 12, 2018 · Past |
| Sherilyn McCoy Other companies: Kimberly-Clark Corporation (Director · Since at least Sep 12, 2018); Stryker Corporation (Lead Independent Director · Since at least May 2, 2018); Certara, Inc. (Director · Dec 11, 2020 – May 18, 2021 · Past); NovoCure Limited (Director · May 31, 2018 – Jun 9, 2021 · Past); Avon Products Inc (CEO, Director · Apr 23, 2012 – Apr 23, 2017 · Past) | Member, Executive Committee · Jan 2, 2008 – Feb 9, 2012 · Past |
| D Scott Davis Other companies: Honeywell Aerospace Inc (Director · Since at least Jun 29, 2026); Honeywell International Inc. (Director · Since at least Nov 10, 2015); United Parcel Service, Inc. (Director · Feb 18, 2016 – Mar 18, 2016 · Past); EndoChoice Holdings Inc (Director · Aug 14, 2015 – Nov 22, 2016 · Past) | Director · Feb 8, 2016 – Apr 25, 2024 · Past |
| Paula A. Johnson Other companies: Maze Therapeutics, Inc. (Director · Since at least Aug 13, 2026); ABIOMED Inc (Director · Apr 26, 2021 – Dec 22, 2022 · Past); Eaton Vance Corp (Director · May 15, 2019 – Feb 12, 2021 · Past); West Pharmaceutical Services, Inc. (Director · May 7, 2019 – May 5, 2020 · Past) | President, Wellesley College · Since at least Feb 14, 2023 |
| Hubert Joly Other companies: S&P Global Inc. (Director · Since at least Jan 2, 2026); Ralph Lauren Corporation (Director · Since at least Jun 30, 2009); Best Buy Co., Inc. (Director · Sep 4, 2012 – May 28, 2020 · Past) | Director · Since at least Dec 5, 2019 |
| Mark A. Weinberger Other companies: JPMorgan Chase & Co. (Director · Since at least Jan 16, 2024); MetLife, Inc. (Director · Since at least Aug 21, 2019); Accelerate Acquisition Corp (Director · Mar 17, 2021 – Dec 23, 2022 · Past) | Director · Since at least Dec 5, 2019 |
| Nadja West Other companies: Tempus AI, Inc. (Director · Since at least Jun 13, 2024); Tenet Healthcare Corporation (Director · Since at least Oct 8, 2019); Nucor Corporation (Director · Since at least Sep 5, 2019) | Director · Since at least Dec 3, 2020 |
| Colleen A Goggins Other companies: IQVIA Holdings, Inc. (Director · Since at least Jul 25, 2017); Bausch Health Companies Inc. (Director · May 20, 2014 – May 22, 2015 · Past) | Member, Executive Committee · Jun 29, 2007 – Jan 10, 2011 · Past |
All 35 people
| Person | Seat |
|---|---|
| Daniel E. Pinto Other companies: Intercontinental Exchange Inc. (Director · Since at least May 15, 2026); JPMorgan Chase & Co. (President & COO · Since at least Jul 27, 2012) | Director · Since at least Jul 1, 2025 |
| Darius Adamczyk Other companies: Garrett Motion Inc. (Director · Apr 30, 2021 – May 26, 2021 · Past); Honeywell International Inc. (Director · Apr 7, 2014 – Jun 7, 2024 · Past) | Director · Feb 15, 2022 – Apr 25, 2024 · Past |
| Gary J. Pruden Other companies: Lantheus Holdings, Inc. (Director · Since at least Feb 26, 2018); Motus GI Holdings, Inc. (Director · Feb 13, 2018 – Mar 5, 2024 · Past) | Exec VP, WW Chair, Med Devices · Apr 28, 2016 – Feb 28, 2017 · Past |
| Joseph J. Wolk Other companies: Prudential Financial, Inc. (Executive Vice President and Chief Financial Officer · Since at least Sep 30, 2025); Kenvue Inc. (Director · May 23, 2024 – May 23, 2024 · Past) | Exec VP, CFO · Since at least Feb 8, 2024 |
| Mary C. Beckerle Other companies: Huntsman Corporation (Director · Since at least Feb 15, 2024); Exelixis, Inc. (Director · Since at least Jan 5, 2024) | Director · Since at least Apr 25, 2024 |
| Michael E Sneed Other companies: Kenvue Inc. (Director · Since at least May 8, 2023); Wayfair Inc. (Director · Since at least Nov 11, 2020) | EVP, Global Corp Aff & CCO · Jul 2, 2018 – Feb 12, 2021 · Past |
| Peter Fasolo Other companies: Kenvue Inc. (Director · May 8, 2023 – May 23, 2024 · Past); HireRight Holdings Corp (Director · Oct 28, 2021 – May 25, 2023 · Past) | Exec VP, Chief HR Officer · Nov 1, 2013 – Feb 15, 2024 · Past |
| John C. Reed Other companies: Madrigal Pharmaceuticals, Inc. (Director · Since at least Aug 11, 2026) | EVP, Innovative Medicine, R&D · Since at least Apr 3, 2023 |
| Thibaut Mongon Other companies: Kenvue Inc. (Chief Executive Officer, Director · May 3, 2023 – Mar 10, 2025 · Past) | Exec VP, WW Chair, Cons Health · Feb 10, 2020 – Feb 13, 2023 · Past |
| Vanessa Broadhurst Other companies: Zoetis Inc. (Director · Since at least Jul 25, 2025) | Executive Vice President, Global Corporate Affairs · Since at least Feb 9, 2026 |
| Christina Zamarro | Chief Financial Officer · Jun 30, 2026 – Nov 5, 2026 · Past |
| Elizabeth Forminard | Executive Vice President, Chief Legal Officer · Since at least Aug 7, 2026 |
| Eugene A. Woods | Advocate Health · Until Aug 14, 2026 · Past |
| James Swanson | Executive Vice President, Chief Information Officer · Since at least Feb 9, 2026 |
| Jennifer L Taubert | EVP, WWC. Innovative Medicine · Since at least Aug 17, 2026 |
| Joaquin Duato | CEO and Chairman of the Board, Director · Since at least Aug 5, 2026 |
| Kathryn E. Wengel | Executive Vice President, Chief Technical Operations and Risk Officer · Since at least Jun 12, 2026 |
| Kristen Mulholland | Executive Vice President, Chief Human Resources Officer · Since at least Feb 6, 2026 |
| Marillyn A. Hewson | Since at least Nov 5, 2026 |
| Mark B. McClellan | Director, Duke-Robert J. Margolis, MD, Center for Health Policy; Margolis Professor of Business, Medicine and Policy, Duke University · Since at least Nov 4, 2026 |
| Ryan Koors | Vice President, Investor Relations · Since at least Apr 30, 2026 |
| Thomas Cavanaugh | EVP WW Chair, Innovative Med. · Since at least Sep 1, 2026 |
| Tim Schmid | Executive Vice President, Worldwide Chairman, MedTech · Since at least Sep 4, 2026 |
| Tom Cavanaugh | Executive Vice President, Worldwide Chairman, Innovative Medicine · Since at least Oct 27, 2026 |
| William Hait | EVP, Chief EI and Med Officer · Jan 3, 2022 – Feb 15, 2024 · Past |
Log in to ask 6ix AI your own questions about Johnson & Johnson.